Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT04177680
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Registry
-
NCT04177680
-
- Other papers using this trial's data
- A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04177680. Randomized; no masking; primary purpose treatment. Start 2020-06-03 (actual); primary completion 2020-11-27 (actual). Results posted on 2022-03-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
- Acronym
- ENHANCE-IT
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Omega 3 pentaenoic acid
- Intervention (Drug)
- icosapent ethyl
- Lead sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Collaborator
- Matinas Biopharma, Inc
- Collaborator
- Midwest Biomedical Research
Record details
- Record id
cardio:ct-nct04177680- Content hash
b27b94a0de12173a479d567ddd54c9639594d6d0dfc5730fcc7485c762c9bdf2